Glucagon-like peptide 1 (GLP-1) drugs, such as Ozempic, are intended for type 2 diabetes patients and people with obesity, ...

The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity treatments continue to improve.

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic ...

Ozempic may also help people drink less alcohol. Primary care doctors are concerned about patients accessing GLP-1s through ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

Six percent of Americans have used Ozempic, Wegovy and similar drugs. They’re unwitting experimental subjects.

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...